RecruitingPhase 3NCT06360133

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

A Phase 3, Randomized, Double-Masked, Vehicle-controlled, Multi-center Study Evaluating the Safety and Efficacy of 5% VVN001 in Chinese Subjects With Dry Eye Disease

Sponsor

VivaVision Biotech, Inc

Enrollment

700 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Conditions

Dry Eye

Summary

This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.

Eligibility

Min Age: 30 YearsMax Age: 80 Years

Inclusion Criteria7

Provided written informed consent prior to any study-related procedures.
Are between 30 and 80 years of age.
Have a history of dry eye disease in both eyes.
Have been using artificial tears within 30 days of the screening visit
Have an Eye dryness score ≥50 (0-100 point VAS)
Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the following criteria in the study eye and the same eye at Visit 1 and Visit 2: 1) total CFS (tCFS) score ≥6; 2) any subregion CS score ≥2.5; 3) Schirmer score (without anesthesia) ≥1 and ≤7 mm/5 min.
Have a BCVA in the study eye of ≥4.3 (Standard for Logarithmic Visual Acuity Charts, 5-mark record).

Exclusion Criteria3

Have a known hypersensitivity or contraindication to the IP or components of IP.
Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening visit or are being treated with eye drops for glaucoma in the study eye. Or the subject has had laser or surgery for glaucoma in the study eye within 90 days of the study.
Woman of childbearing potential (WOCP) who are pregnant, lactating, or preparing for pregnant.

Interested in this trial?

Get notified about updates and connect with the research team.